Completed PHASE2 INTERVENTIONAL 2-arm NCT00295854

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

Sponsor: MediciNova

Conditions Interstitial Cystitis

Interventions MN-001 MN-001 BID Placebo

Updated 6 times since 2017 Last updated: Dec 16, 2011 Started: May 31, 2005 Primary completion: Oct 31, 2006 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Interstitial Cystitis and is currently completed. MediciNova leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MediciNova

Data source: MediciNova

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Atlanta, United States , Aventura, United States , Birmingham, United States , Boulder, United States , Boynton Beach, United States , Centralia, United States , Cincinnati, United States , Corsicana, United States , Evanston, United States and 18 more locations